Cargando…
Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway
PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590136/ https://www.ncbi.nlm.nih.gov/pubmed/37867629 http://dx.doi.org/10.2147/DMSO.S431423 |
_version_ | 1785123935715590144 |
---|---|
author | Liang, Mingjie Zhan, Wenjing Wang, Lexun Bei, Weijian Wang, Weixuan |
author_facet | Liang, Mingjie Zhan, Wenjing Wang, Lexun Bei, Weijian Wang, Weixuan |
author_sort | Liang, Mingjie |
collection | PubMed |
description | PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of T2DM, remains poorly understood. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is responsible for prostaglandin E(2) (PGE(2)) inactivation. A recent study has reported that inhibition of 15-PGDH promoted hepatic glycogen synthesis and improved T2DM. Therefore, herein, we aimed to investigate whether Rb1 ameliorated T2DM through 15-PGDH/PGE(2)-regulated hepatic glycogen synthesis. METHODS: By combining streptozotocin with a high-fat diet, we successfully established a mouse model for T2DM. Afterward, these mice were administered Rb1 or metformin for 8 weeks. An insulin-resistant cell model was established by incubating LO2 cells with palmitic acid. Liver glycogen and PGE(2) levels, the expression levels of 15-PGDH, serine/threonine kinase AKT (AKT), and glycogen synthase kinase 3 beta (GSK3β) were measured. Molecular docking was used to predict the binding affinity between 15-PGDH and Rb1. RESULTS: Rb1 administration increased the phosphorylation levels of AKT and GSK3β to enhance glycogen synthesis in the liver of T2DM mice. Molecular docking indicated that Rb1 had a high affinity for 15-PGDH. Moreover, Rb1 treatment resulted in the suppression of elevated 15-PGDH levels and the elevation of decreased PGE(2) levels in the liver of T2DM mice. Furthermore, in vitro experiments showed that Rb1 administration might enhance glycogen production by modulating the 15-PGDH/PGE(2)/PGE(2) receptor EP4 pathway. CONCLUSION: Our findings indicate that Rb1 may enhance liver glycogen production through a 15-PGDH-dependent pathway to ameliorate T2DM, thereby offering a new explanation for the positive impact of Rb1 on T2DM and supporting its potential as an effective therapeutic approach for T2DM. |
format | Online Article Text |
id | pubmed-10590136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-105901362023-10-22 Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway Liang, Mingjie Zhan, Wenjing Wang, Lexun Bei, Weijian Wang, Weixuan Diabetes Metab Syndr Obes Original Research PURPOSE: Ginsenoside Rb1 (Rb1), one of the crucial bioactive constituents in Panax ginseng C. A. Mey., possesses anti-type 2 diabetes mellitus (T2DM) property. Nevertheless, the precise mechanism, particularly the impact of Rb1 on hepatic glycogen production, a crucial process in the advancement of T2DM, remains poorly understood. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is responsible for prostaglandin E(2) (PGE(2)) inactivation. A recent study has reported that inhibition of 15-PGDH promoted hepatic glycogen synthesis and improved T2DM. Therefore, herein, we aimed to investigate whether Rb1 ameliorated T2DM through 15-PGDH/PGE(2)-regulated hepatic glycogen synthesis. METHODS: By combining streptozotocin with a high-fat diet, we successfully established a mouse model for T2DM. Afterward, these mice were administered Rb1 or metformin for 8 weeks. An insulin-resistant cell model was established by incubating LO2 cells with palmitic acid. Liver glycogen and PGE(2) levels, the expression levels of 15-PGDH, serine/threonine kinase AKT (AKT), and glycogen synthase kinase 3 beta (GSK3β) were measured. Molecular docking was used to predict the binding affinity between 15-PGDH and Rb1. RESULTS: Rb1 administration increased the phosphorylation levels of AKT and GSK3β to enhance glycogen synthesis in the liver of T2DM mice. Molecular docking indicated that Rb1 had a high affinity for 15-PGDH. Moreover, Rb1 treatment resulted in the suppression of elevated 15-PGDH levels and the elevation of decreased PGE(2) levels in the liver of T2DM mice. Furthermore, in vitro experiments showed that Rb1 administration might enhance glycogen production by modulating the 15-PGDH/PGE(2)/PGE(2) receptor EP4 pathway. CONCLUSION: Our findings indicate that Rb1 may enhance liver glycogen production through a 15-PGDH-dependent pathway to ameliorate T2DM, thereby offering a new explanation for the positive impact of Rb1 on T2DM and supporting its potential as an effective therapeutic approach for T2DM. Dove 2023-10-17 /pmc/articles/PMC10590136/ /pubmed/37867629 http://dx.doi.org/10.2147/DMSO.S431423 Text en © 2023 Liang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Liang, Mingjie Zhan, Wenjing Wang, Lexun Bei, Weijian Wang, Weixuan Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title | Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title_full | Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title_fullStr | Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title_full_unstemmed | Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title_short | Ginsenoside Rb1 Promotes Hepatic Glycogen Synthesis to Ameliorate T2DM Through 15-PGDH/PGE(2)/EP4 Signaling Pathway |
title_sort | ginsenoside rb1 promotes hepatic glycogen synthesis to ameliorate t2dm through 15-pgdh/pge(2)/ep4 signaling pathway |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590136/ https://www.ncbi.nlm.nih.gov/pubmed/37867629 http://dx.doi.org/10.2147/DMSO.S431423 |
work_keys_str_mv | AT liangmingjie ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway AT zhanwenjing ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway AT wanglexun ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway AT beiweijian ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway AT wangweixuan ginsenosiderb1promoteshepaticglycogensynthesistoamelioratet2dmthrough15pgdhpge2ep4signalingpathway |